Ovarian Cancer Trial, Recruiting NCT06962059 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06962059
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have ovaries
  • People who have undergone genetic testing and do not carry any of the gene mutations listed in the exclusion criteria below

Who may not be able to join:

  • People who carry certain genetic mutations known to increase the risk of ovarian cancer, including BRCA1, BRCA2, BRIP1, PALB2, ATM, or those associated with Lynch Syndrome (MLH1, MSH2/EPCAM, MSH6)
  • People who have not had genetic testing done, or whose genetic status is unknown
  • People who have previously been diagnosed with cancer
  • People who have previously received any cancer treatment
  • People who are currently using hormone replacement therapy (HRT)
  • People who have used antibiotics in the month before providing a sample for the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Susan Domchek, MD, University of Pennsylvania

Phone: 215-360-0422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
21 April 2025
Est. completion
15 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Microbiome Involvement; Predictive Model

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov